Vitamin B12 measurements across neurodegenerative disorders

Abstract

Background: Vitamin B12 deficiency causes a number of neurological features including cognitive and psychiatric disturbances, gait instability, neuropathy, and autonomic dysfunction. Clinical recognition of B12 deficiency in neurodegenerative disorders is more challenging because it causes defects that overlap with expected disease progression. We sought to determine whether B12 levels at the time of diagnosis in patients with Parkinson's disease (PD) differed from those in patients with other neurodegenerative disorders.

Methods: We performed a cross-sectional analysis of B12 levels obtained around the time of diagnosis in patients with PD, Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB), Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), or Mild Cognitive Impairment (MCI). We also evaluated the rate of B12 decline in PD, AD, and MCI.

Results: In multivariable analysis adjusted for age, sex, and B12 supplementation, we found that B12 levels were significantly lower at time of diagnosis in patients with PD than in patients with PSP, FTD, and DLB. In PD, AD, and MCI, the rate of B12 decline ranged from - 17 to - 47 pg/ml/year, much greater than that reported for the elderly population.

Conclusions: Further studies are needed to determine whether comorbid B12 deficiency affects progression of these disorders.

Keywords: Cyanocobalamin; Subacute combined degeneration; Vitamin B12.

Fig. 1

Rate of B12 Decline in PD, MCI, and AD patients. Plots showing individual declines of B12 in patients with PD, MCI, and AD. Median (interquartile range) rate of decline were − 17 (−35, − 0.4), −47 (−112, −8), and − 29 (− 124, 2.4) pg/ml/year for PD, MCI, and AD, respectively